The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: Connecting the dots

Molecular Cancer

Volumn 5, Issue , 2006, Pages

  Costello, Leslie C ^a   Franklin, Renty B ^a  

^a UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITRIC ACID; ZINC; ZINC TRANSPORTER;

BIOENERGY; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL GROWTH; CELL INVASION; CELL METABOLISM; CELL MIGRATION; CELL PROLIFERATION; CELL TRANSFORMATION; GENE MUTATION; HUMAN; NONHUMAN; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; REVIEW; TUMOR SUPPRESSOR GENE;

ACETYL COENZYME A; CATION TRANSPORT PROTEINS; CITRIC ACID; GENES, TUMOR SUPPRESSOR; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; OXIDATION-REDUCTION; PROSTATE; PROSTATIC NEOPLASMS; ZINC;

MAMMALIA;

EID: 33745512125     PISSN: 14764598     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-5-17     Document Type: Review

References (65)

1. Ostrander EA, Stanford JL: Genetics of prostate cancer: Too many loci; too few genes. Am J Hum Genet 2000, 67:1367-1375.
2. Porkka KP, Visakorpi T: Molecular mechanisms of prostate cancer. European Urol 2004, 45:683-691.
3. Warburg O, Wind F, Negelein E: Uber den Stoffwechsel von Tumoren im Korper. Klin Woch 1926, 5:829-832.
4. Pedersen PL: Tumor mitochondria and the bioenergetics of cancer cells. Prog Exp Tumor Res 1978, 22:190-274.
5. Modica-Napolitano JS, Singh KK: Mitochondrial dysfunction in cancer. Mitochondrion 2004, 4:755-762.
6. Dang CV, Samenza GL: Oncogenic alterations of metabolism. Trends BioSci 1999, 24:68-72.
7. Baggetto LG: Deviant energetic metabolism of glycolytic cancer cells. Biochimie 1992, 74:959-974.
8. Costello LC, Franklin RB: "Why Do Tumor Cells Glycolyze?": From Glycolysis Through Citrate To Lipogenesis. Mol Cell Biochem 2005, 280:1-8.
9. Franklin RB, Milon B, Feng P, Costello LC: Zinc and zinc transporter in normal prostate function and the pathogenesis of prostate cancer. Frontiers in Bioscience 2005, 10:2230-2239.
10. Costello LC, Feng P, Franklin RB: Mitochondrial Function, Zinc, and Intermediary Metabolism. Relationships in Normal Prostate and Prostate Cancer. Mitochondrion 2005, 5:143-153.
11. Costello LC, Franklin RB, Feng P, Tan M, Bagasra O: Zinc and Prostate Cancer: A critical scientific, medical and public interest issue. Cancer Causes Control 2005, 16:901-915.
12. Costello LC, Franklin RB: The intermediary metabolism of the prostate: A key to understanding the pathogenesis and progression of prostate malignancy. Oncology 2001, 59:269-282.
13. Huggins C: The prostatic secretion. Harvey Lect 1947, 42:148-193.
14. Harkonen PL, Isoltalo A, Santti R: Studies on the mechanism of testosterone action on glucose metabolism in the rat ventral prostate. J Steroid Biochem Mol Bioi 1975, 6:1405-1413.
15. Harkonen PL: Androgenic control of glycolysis, the pentose cycle and pyruvate dehydrogenase in the rat ventral prostate. J Steroid Biochem Mol Bio 1981, 14:1075-1084.
16. Harkonen PL, Kostian ML, Santti RS: Indirect androgenic control of citrate accumulation in rat ventral prostate. Arch Androl 1982, 8:107-116.
17. Costello LC, Franklin RB: Prostate epithelial cells utilize glucose and aspartate as the carbon sources for net citrate production. Prostate 1989, 15:335-342.
18. Franklin RB, Lao L, Costello LC: Evidence for two aspartate transport systems in prostate epithelial cells. Prostate 1990, 16:137-146.
19. Lao L, Franklin RB, Costello LC: A high affinity L-aspartate transporter in prostate epithelial cells which is regulated by testosterone. Prostate 1993, 22:53-63.
20. Costello LC, Lao L, Franklin RB: Citrate modulation of high affinity aspartate transport in prostate epithelial cells. Cell Mol Biol 1993, 39:515-524.
21. Franklin RB, Zou J, Yu Z, Costello LC: EAAC1 is expressed in rat and human prostate epithelial cells; functions as a high-affinity L-aspartate transporter; and is regulated by prolactin and testosterone. BMC Biochemistry 2006, 7:10.
22. Costello LC, Liu Y, Franklin RB, Kennedy MC: Zinc inhibition of mitochondrial aconitase and its importance in citrate metabolism of prostate epithelial cells. J Biol Chem 1997, 272:28875-28881.
23. Singh KK, Desouki MM, Franklin RB, Costello LC: Mitochondrial Aconitase and Citrate Metabolism in Malignant and Nonmalignant Human Prostate Tissues. Mol Cancer 2006, 5:14. 4
24. Halliday KR, Fenoglio-Preiser C, Sillerud LO: Differentiation of human tumors from nonmalignant tissue by natural-abundance 13C NMR spectroscopy. Magn Reson Med 1988, 7:384-411.
25. Swinnen JV, Heemers H, Heyns W, Verhoeven G: Androgen regulation of lipogenesis. Adv Exp Med Biol 2002, 506(Pt A):379-387.
26. Parlo RA, Coleman PS: Enhanced rate of citrate export from cholesterol-rich hepatoma mitochondria. J Biol Chem 1984, 259:997-10003.
27. Parlo RA, Coleman PS: Continuous pyruvate carbon flux to newly synthesized cholesterol and the suppressed evolution of pyruvate-generated CO2 in tumors: further evidence for a persistent truncated Krebs cycle in hepatomas. Biochim Biophys Acta 1986, 886:169-176.
28. Baggetto LG: Deviant energetic metabolism of glycolytic cancer cells. Biochimie 1992, 74:959-974.
29. Board M, Humm S, Newsholme EA: Maximum activities of key enzymes of glycolysis, glutaminolysis, pentose phosphate pathway and tricarboxylic acid cycle in normal, neoplastic and suppressed cells. Biochem J 1990, 265:503-509.
30. Kelleher JK, Bryan BM 3rd, Mallet RT, Holleran AL, Murphy AN, Fiskum G: Analysis of tricarboxylic acid-cycle metabolism of hepatoma cells by comparison of 14CO2 ratios. Biochem J 1987, 246:633-639.
31. Dietzen DJ, Davis EJ: Oxidation of pyruvate, malate, citrate, and cytosolic reducing equivalents by AS-30D hepatoma mitochondria. Arch Biochem Biophys 1993, 305:91-102.
32. Hernanz A, de la Fuente M: Characterization of aconitate hydratase from mitochondria and cytoplasm of ascites tumor cells. Biochem Cell Biol 1988, 66:792-795.
33. Oikawa E, Iijima H, Suzuki T, Sasano H, Sato H, Kamataki A, Nagura H, Kang MJ, Fujino T, Suzuki H, Yamamoto TT: A novel acyl-CoA synthetase, ACS5, expressed in intestinal epithelial cells and proliferating preadipocytes. J Biochem (Tokyo) 1998, 124:679-685.
34. Loikkanen I, Haghighi S, Vainio S, Pajunen A: Expression of cytosolic acetyl-CoA synthetase gene is developmentally regulated. Mech Dev 2002, 115:139-141.
35. Sone H, Shimano H, Sakakura Y, Inoue N, Amemiya-Kudo M, Yahagi N, Osawa M, Suzuki H, Yokoo T, Takahashi A, Iida K, Toyoshima H, Iwama A, Yamada N: Acetyl-coenzyme A synthetase is a lipogenic enzyme controlled by SREBP-I and energy status. Am J Physiol Endocrinol Metab 2002, 282:E222-230.
36. Pomare EW, Branch WJ, Cummings JH: Carbohydrate fermentation in the human colon and its relation to acetate concentrations in venous blood. J Clin Invest 1985, 75:1448-1454.
37. Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak D, Hingorani SR, Tuveson DA, Thompson CB: ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 2005, 8:311-321.
38. Costello LC, Franklin RB, Narayan P: Citrate in the diagnosis of prostate cancer. Prostate 1999, 38:237-245.
39. Costello LC, Franklin RB, Kurhanewicz J: The metabolic characterization of prostate malignancy by magnetic resonance spectroscopy. In Encyclopedia of Cancer Volume 1. Edited by: Betino JR. Academic Press, NY; 2002:167-178.
40. Kurhanewicz J, Swanson MG, Nelson SJ, Vigneron DB: Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J Mag Reson Imag 2002, 16:451-463.
41. Costello LC, Franklin RB: Concepts of citrate production and secretion by prostate. 2. Hormone relationships in normal and neoplastic prostate. Prostate 1991, 19:181-205.
42. Kurhanewicz J, Vigneron DB, Hricak H, Narayan P, Carroll P, Nelson SJ: Three dimensional hydrogen-I MR spectroscopic imaging of the in situ human prostate with high spatial resolution. Radiology 1996, 198:795-805.
43. Heerschap A, Jager GJ, Van Der Graaf M, Barentsz JO, De La Rosette J, Oosterhoff GO, Ruijter E, Ruijs S: In vivo proton MR spectroscopy reveals altered metabolite content in malignant prostate tissue. Anticancer Res 1997, 17:1455-1460.
44. Liney GP, Turnbull LW, Lowry M, Turnbull LS, Knowles AJ, Horsman A: In vivo quantification of citrate concentration and water T2 relaxation time of the pathologic prostate gland using 1H MRS and MRI. Magn Reson Imaging 1997, 15:1177-1186.
45. Zaichick VYe, Sviridova TV, Zaichick SV: Zinc in the human prostate gland: normal, hyperplastic and cancerous. Int Urol Nephrol 1997, 29(5):565-74.
46. Franklin RB, Feng P, Milon BC, Desouki MM, Singh KK, Kajdacsy-Balla A, Bagasra O, Costello LC: hZIP1 zinc uptake transporter down regulation and zinc depletion in prostate cancer. Mol Cancer 2005, 4:32.
47. Costello LC, Guan Z, Kukoui B, Feng P, Franklin RB: Terminal Oxidation and the Effects of Zinc in Prostate and Liver Mitochondria. Mitochondrion 2004, 4:331-338.
48. Liang J-Y, Liu Y-Y, Zou J, Franklin RB, Costello LC, Feng P: Inhibitory effect of zinc on human prostatic carcinoma cell growth. Prostate 1999, 40:200-207.
49. Feng P, Liang J-Y, Li T-L, Guan Z-X, Zou J, Franklin RB, Costello LC: Zinc induces mitochondria apoptogenesis in prostate cells. Mol Urol 2000, 4:31-36.
50. Feng P, Li T-L, Guan Z-X, Franklin RB, Costello LC: Direct effect of zinc on mitochondrial apoptogenesis in prostate cells. Prostate 2002, 52:311-318.
51. Huang L, Kirschke CP, Zhang Y: Decreased intracellular zinc in human tumorigenic prostate epithelial cells: a possible role in prostate cancer progression. Cancer Cell Int 2006, 31:10. [Epub ahead of print]
52. Uzzo RG, Leavis P, Hatch W, Gabai VL, Dulin N, Zvartau N, Kolenko VM: Zinc inhibits nuclear factor-kappa B activation and sensitizes prostate cancer cells to cytotoxic agents. Clin Cancer Res 2002, 8:3579-3583.
53. Ishii K, Otsuka T, Iguchi K, Usui S, Yamamoto H, Sugimura Y, Yoshikawa K, Hayward SW, Hirano K: Evidence that the prostate-specific antigen (PSA)/Zn2+ axis may play a role in human prostate cancer cell invasion. Cancer Lett 2004, 207:79-87.
54. Ishii K, Usui S, Sugimura Y, Yoshida S, Hioki T, Tatematsu M, Yamamoto H, Hirano K: Aminopeptidase N regulated by zinc in human prostate participates in tumor cell invasion. Int J Cancer 2001, 92:49-54.
55. Uzzo RG, Crispen PL, Golovine K, Makhov P, Horwitz EM, Kolenko VM: Diverse effects of zinc on NF-{kappa}B and AP-1 transcription factors: implications for prostate cancer progression. Carcinogenesis. 2006 Apr 10; [Epub ahead of print]
56. Costello LC, Liu Y, Zou J, Franklin RB: Evidence for a zinc uptake transporter in human prostate cancer cells which is regulated by prolactin and testosterone. J Biol Chem 1999, 274:17499-17504.
57. Franklin RB, Ma J, Zou J, Guan Z, Kukoyi BI, Feng P, Costello LC: Human ZIP1 is a major zinc uptake transporter for the accumulation of zinc in prostate cells. J Inorgan Biochem 2003, 96:435-442.
58. Milon B, Dhermy D, Pountney D, Bourgeois M, Beaumont C: Differential subcellular localization of hZip1 in adherent and non-adherent cells. FEBS Lett 2001, 507:241-246.
59. Rishi I, Baidouri H, Abbasi JA, Bullard-Dilland R, Kajdacsy-Balla A, Pestaner JP, Skacel M, Tubbs R, Bagasra O: Prostate cancer in African American men is associated with downregulation of zinc transporters. Appl Immunohistochem Mol Morphol 2003, 11:253-260.
60. Li H, Myeroff L, Smiraglia D, Romero MF, Pretlow TP, Kasturi L, Lutterbaugh J, Rerko RM, Casey G, Issa JP, Willis J, Willson JK, Plass C, Markowitz SD: SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Pro of the National Acad of Sci (USA) 2003, 100:8412-8417.
61. Coady MJ, Chang M-H, Charron FM, Consuelo Plata, Bernadette Wallendorff, Jerome Sah Frank, Sanford Markowitz D, Michael Romero F, Jean-Yves Lapointe: The human tumour suppressor gene SLC5A8 expresses a Na+-monocarboxylate cotransporter. J Physiol (Lond) 2004, 557:719-731.
62. Ganapathy V, Gopal E, Miyauchi S, Prasad PD: Biological functions of SLC5A8, a candidate tumour suppressor. Biochemical Society Transactions 2005, 33(Pt 1):237-240.
63. Miyauchi S, Gopal E, Fei YJ, Ganapathy V: Functional identification of SLC5A8, a tumor suppressor down-regulated in colon cancer, as a Na(+)-coupled transporter for short-chain fatty acids. Journal of Biological Chemistry 2004, 279:13293-13296.
64. Ueno M, Toyota M, Akino K, Suzuki H, Kusano M, Satoh A, Mita H, Sasaki Y, Nojima M, Yanagihara K, Hinoda Y, Tokino T, Imai K: Aberrant methylation and histone deacetylation associated with silencing of SLC5A8 in gastric cancer. Tumour Biology 2004, 253:134-140.
65. Porra V, Ferraro-Peyret C, Durand C, Selmi-Ruby S, Giroud H, Berger-Dutrieux N, Decaussin M, Peix JL, Bournaud C, Orgiazzi J, Borson-Chazot F, Dante R, Rousset B: Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas. Journal of Clinical Endocrinology & Metabolism 2005, 905:3028-3035.